EGFR-TKIs resistance via EGFR-independent signaling pathways

Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qian, Yu, Shengnan, Zhao, Weiheng, Qin, Shuang, Chu, Qian, Wu, Kongming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817859/
https://www.ncbi.nlm.nih.gov/pubmed/29455669
http://dx.doi.org/10.1186/s12943-018-0793-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817859/
https://www.ncbi.nlm.nih.gov/pubmed/29455669
http://dx.doi.org/10.1186/s12943-018-0793-1

Ejemplares similares